About ADAM DEC1
ADAM DEC1 (ADAMDEC1) is a protein
from Homo sapiens identified by UniProt accession
O15204, 470 residues long.
MolForge cross-references it against 0 known binders and
199 disease associations.
Target properties
| Protein name | ADAM DEC1 |
| UniProt accession | O15204 |
| Gene | ADAMDEC1 |
| Organism | Homo sapiens |
| Length | 470 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (199)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.38
- inflammatory bowel disease · score 0.10
- non-small cell lung carcinoma · score 0.08
- glioblastoma multiforme · score 0.07
- body height · score 0.07
- Autosomal recessive early-onset inflammatory bowel disease · score 0.07
- central nervous system cancer · score 0.06
- neoplasm · score 0.06
- isolated agammaglobulinemia · score 0.06
- Immunodeficiency by defective expression of HLA class 2 · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O15204-F1 | alphafold | PREDICTED | 80.18 | — |
Amino-acid sequence (470 residues)
MLRGISQLPA VATMSWVLLP VLWLIVQTQA IAIKQTPELT LHEIVCPKKL HILHKREIKN NQTEKHGKEE RYEPEVQYQM ILNGEEIILS LQKTKHLLGP DYTETLYSPR GEEITTKPEN MEHCYYKGNI LNEKNSVASI STCDGLRGYF THHHQRYQIK PLKSTDEKEH AVFTSNQEEQ DPANHTCGVK STDGKQGPIR ISRSLKSPEK EDFLRAQKYI DLYLVLDNAF YKNYNENLTL IRSFVFDVMN LLNVIYNTID VQVALVGMEI WSDGDKIKVV PSASTTFDNF LRWHSSNLGK KIHDHAQLLS GISFNNRRVG LAASNSLCSP SSVAVIEAKK KNNVALVGVM SHELGHVLGM PDVPFNTKCP SGSCVMNQYL SSKFPKDFST SCRAHFERYL LSQKPKCLLQ APIPTNIMTT PVCGNHLLEV GEDCDCGSPK ECTNLCCEAL TCKLKPGTDC GGDAPNHTTE
Explore ADAM DEC1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets